Optimi Health Corp. announced plans to initiate a Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The Health Canada-authorized study is expected to begin in 2027 and will enroll up to 100 participants, primarily veterans and frontline workers such as military personnel, police, paramedics, firefighters, and healthcare workers. Participants will receive the company's synthetic MDMA HCl during two supervised sessions combined with psychotherapy. The primary efficacy endpoint is the change in Clinician-Administered PTSD Scale (CAPS-5) scores. This follows a recent announcement regarding a Phase 2 trial for natural psilocybin in major depressive disorder, as management aims to submit both products for registration. Optimi Health Corp. operates in the pharmaceutical industry, specifically manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies.

Optimi Health Corp. announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD). Authorized by Health Canada, the study will enroll up to 200 participants across multiple sites in Canada, with dosing expected to be completed by the end of 2027. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale total score from baseline. CEO Dane Stevens stated this represents the largest clinical commitment Optimi has made to date and that the company will supply its own naturally derived psilocybin manufactured at its GMP facility, retaining exclusive ownership of trial results. The company indicated it can comfortably fund the trial with current cash on hand. Optimi Health Corp. is a commercial-stage pharmaceutical manufacturer focused on producing and distributing regulated psychedelic drug products for mental health therapies.

On August 13, 2026, Optimi Health Corp. entered into a common shares purchase agreement with Seven Knots, LLC, establishing an equity line of credit allowing the Company to sell up to US$100 million of its common shares at its discretion. The facility permits draws of up to US$2 million per transaction, priced at 97% of the lower of the daily low or volume-weighted average price, subject to a floor equal to 85% of the prior day's closing price. To secure Seven Knots' commitment, Optimi issued an unsecured convertible promissory note with a principal amount of US$1.5 million and agreed to issue a second note for US$0.5 million if gross proceeds exceed US$7 million. These notes mature in 24 months and are convertible at 95% of the 20-day VWAP, subject to a $3.00 floor price. Joseph Gunnar & Co. LLC serves as the exclusive placement agent, entitled to a 3% fee on gross proceeds. Optimi Health Corp. is a commercial-stage pharmaceutical manufacturer specializing in regulated psychedelic drug products for mental health therapies.

Optimi Health Corp. filed a Form 6-K containing its unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the nine-month period ended June 30, 2026. The company reported revenue of $239,700 CAD, down from $490,330 in the prior-year period, alongside a net loss of $5,715,536 compared to a $2,362,664 loss previously. During the period, Optimi raised $20.7 million in gross proceeds from an underwritten public offering on the Nasdaq Capital Market and settled $450,000 in convertible debt by issuing 100,000 common shares. The filing also confirms that on May 19, 2026, the company executed a one-for-thirty reverse stock split of its outstanding securities. Optimi Health Corp. operates as a pharmaceutical drug manufacturer specializing in controlled substances, specifically MDMA and botanical psilocybin.

Optimi Health Corp. disclosed that CEO Dane Stevens purchased 3,800 common shares in the open market at CDN$6.70 per share on August 5, 2026, through his controlled entity Cathay Visions Enterprises Ltd. Following this transaction, Mr. Stevens beneficially holds a total of 456,347 common shares. This is a routine insider trading disclosure and does not contain material information affecting the company's value or operations. Optimi Health Corp. operates in the healthcare industry, focusing on digital health solutions.